Prof. Nan Du 杜楠
Chief Physician, Professor
Department of Medical Oncology, Chinese PLA General Hospital (301 Hospital), First Medical Center, Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Treatment of thoracic, abdominal tumors, and melanoma. Specializes in biological targeted therapy, specific immunotherapy, and anti-angiogenic therapy for malignant pleural effusion, ascites, and brain metastases.
Dr. Du is Director of the Second Oncology Department, Professor, and doctoral supervisor. Holds a medical doctorate. Leads research on active immunotherapy and laser in situ immunotherapy for melanoma. Has led multiple national and military research projects, authored two books, and published over 100 papers.
Professional roles
- Vice Chair, Translational Medicine Professional Committee, Beijing Medical Doctor Association
- Chair, Tumor Precision Medicine Committee, China Rehabilitation and Aging Committee
- Standing Committee Member, Translational Medicine and Palliative Rehabilitation Medicine Professional Committee, Chinese Society of Clinical Oncology (CSCO)
- Member, Melanoma Professional Committee, Chinese Society of Clinical Oncology (CSCO)
Name order: in Chinese the family name comes first (Du Nan). Papers usually list the name as Nan Du or Du N.
Selected publications
37 papers on PubMed matched by name and affiliation; 6 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Korean Neurosurg Soc, 2025 (senior author): Spermine Synthase : A Potential Prognostic Marker for Lower-Grade Gliomas. PubMed 39492653
- Medicine (Baltimore), 2021 (senior author): Multiple genetic variants predict the progression-free survival of bevacizumab plus chemotherapy in advanced ovarian cancer: A retrospective study. PubMed 34477158
- Front Cell Dev Biol, 2020 (senior author): Identifying Cancer-Related lncRNAs Based on a Convolutional Neural Network. PubMed 32850792
- Biochem Biophys Res Commun, 2019 (senior author): MiR-150-5p regulates melanoma proliferation, invasion and metastasis via SIX1-mediated Warburg Effect. PubMed 31128917
- Medicine (Baltimore), 2016 (senior author): Combination use of paclitaxel and avastin enhances treatment effect for the NSCLC patients with malignant pleural effusion. PubMed 27893676
- J Cancer Res Ther, 2016 (senior author): Efficacy of icotinib versus traditional chemotherapy as first-line treatment for preventing brain metastasis from advanced lung adenocarcinoma in patients with epidermal growth factor receptor-sensitive mutation. PubMed 28054523
- Medicine (Baltimore), 2015 (senior author): Neoadjuvant Therapy of DOF Regimen Plus Bevacizumab Can Increase Surgical Resection Ratein Locally Advanced Gastric Cancer: A Randomized, Controlled Study. PubMed 26496252
- Med Oncol, 2015 (senior author): Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial. PubMed 25609006
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion